lunedì, 26 luglio 2021
24 Agosto 2017

FDA Approves CPX-351 for Two Types of AML

August 3, 2017 – The FDA has approved CPX-351, a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), based on an improvement in overall survival (OS) in a phase III study. The approval, which arrived several months ahead of an FDA deadline, was based on findings from a phase III study comparing CPX-351 with … (leggi tutto)